58 related articles for article (PubMed ID: 38685486)
1. Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial.
Lin JX; Tang YH; Zheng HL; Ye K; Cai JC; Cai LS; Lin W; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Zheng CH; Li P; Huang CM
Nat Commun; 2024 Jan; 15(1):41. PubMed ID: 38167806
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive multi-omics analysis of pyroptosis for optimizing neoadjuvant immunotherapy in patients with gastric cancer.
Wang JB; Gao YX; Ye YH; Zheng QL; Luo HY; Wang SH; Zhang T; Jin QW; Zheng CH; Li P; Lin JX; Chen QY; Cao LL; Yang YH; Huang CM; Xie JW
Theranostics; 2024; 14(7):2915-2933. PubMed ID: 38773976
[No Abstract] [Full Text] [Related]
3. Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer.
An M; Mehta A; Min BH; Heo YJ; Wright SJ; Parikh M; Bi L; Lee H; Kim TJ; Lee SY; Moon J; Park RJ; Strickland MR; Park WY; Kang WK; Kim KM; Kim ST; Klempner SJ; Lee J
Cancer Discov; 2024 May; 14(5):766-785. PubMed ID: 38319303
[TBL] [Abstract][Full Text] [Related]
4. Donafenib as neoadjuvant therapy in locally advanced thyroid cancer: protocol for the DONATHYCA phase II prospective single-arm trial in China.
Yu J; Liu H; Wu Y
BMJ Open; 2024 May; 14(5):e081090. PubMed ID: 38806431
[TBL] [Abstract][Full Text] [Related]
5. ASO Author Reflections: The Role of Neoadjuvant Chemotherapy Among Elderly Patients with Locally Advanced Gastric Cancer.
Rawicz-Pruszyński K; Pawlik TM
Ann Surg Oncol; 2024 Feb; 31(2):806-807. PubMed ID: 37978107
[No Abstract] [Full Text] [Related]
6. Deciphering gastric inflammation-induced tumorigenesis through multi-omics data and AI methods.
Zhang Q; Yang M; Zhang P; Wu B; Wei X; Li S
Cancer Biol Med; 2023 Aug; 21(4):312-30. PubMed ID: 37589244
[TBL] [Abstract][Full Text] [Related]
7. Evolutionary and immune microenvironment dynamics during neoadjuvant treatment of oesophagael adenocarcinoma.
Barroux M; Househam J; Lakatos E; Ronel T; Baker AM; Salié H; Mossner M; Smith K; Kimberley C; Nowinski S; Berner A; Gunasri V; Jansen M; Caravagna G; Steiger K; Slotta-Huspenina J; Weichert W; Alberstmeier M; Chain B; Friess H; Bengsch B; Schmid R; Siveke J; Quante M; Graham T
Res Sq; 2023 Apr; ():. PubMed ID: 37090678
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive evaluation of a multicenter real-world study: Neoadjuvant immunochemotherapy in locally advanced gastric cancer.
Li K; Lu S; Leng X; Peng L
Int J Surg; 2024 May; ():. PubMed ID: 38775589
[No Abstract] [Full Text] [Related]
9. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
10. Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East.
Fujitani K
Dig Surg; 2013; 30(2):119-29. PubMed ID: 23867588
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center, open-label, single-arm phase II trial.
Zhao Y; Li D; Zhuang J; Li Z; Xia Q; Li Z; Yu J; Wang J; Zhang Y; Li K; Xu S; Li S; Ma P; Cao Y; Liu C; Xu C; Liu Z; Wei J; Zhang C; Qiao L; Gao X; Hou Z; Liu C; Zheng R; Wang D; Liu Y
Clin Transl Med; 2024 May; 14(5):e1674. PubMed ID: 38685486
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study.
Li N; Li Z; Fu Q; Zhang B; Zhang J; Wan XB; Lu CM; Wang JB; Deng WY; Ma YJ; Bie LY; Wang MY; Li J; Xia QX; Wei C; Luo SX
Int J Surg; 2024 Apr; 110(4):2071-2084. PubMed ID: 38320099
[TBL] [Abstract][Full Text] [Related]
13. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
Dos Santos M; Lequesne J; Leconte A; Corbinais S; Parzy A; Guilloit JM; Varatharajah S; Brachet PE; Dorbeau M; Vaur D; Weiswald LB; Poulain L; Le Gallic C; Castera-Tellier M; Galais MP; Clarisse B
BMC Cancer; 2022 May; 22(1):537. PubMed ID: 35549674
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of camrelizumab combined with oxaliplatin and S-1 as neoadjuvant treatment in locally advanced gastric or gastroesophageal junction cancer: A phase II, single-arm study.
Zhong WJ; Lin JA; Wu CY; Wang J; Chen JX; Zheng H; Ye K
Cancer Med; 2024 Feb; 13(3):e7006. PubMed ID: 38400680
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]